<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198701</url>
  </required_header>
  <id_info>
    <org_study_id>PULSED AF</org_study_id>
    <nct_id>NCT04198701</nct_id>
  </id_info>
  <brief_title>Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF</brief_title>
  <acronym>PULSED AF</acronym>
  <official_title>Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multi-center, non-randomized, unblinded worldwide pre-market&#xD;
      clinical study. The purpose of the study is to provide data demonstrating the safety and&#xD;
      effectiveness of the PulseSelect™ PFA System for the treatment of atrial fibrillation (AF).&#xD;
      The study will also provide first in human insights into clinical safety and device function&#xD;
      of the PulseSelect PFA System for pulmonary vein isolation (PVI) as a treatment for AF. To&#xD;
      this end, the clinical study has been designed into phases (Pilot and Pivotal), with each&#xD;
      phase comprising a separate data set that will be analyzed and reported on per the below&#xD;
      objectives.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study begins with a Pilot Phase, followed sequentially by a Pivotal Phase consisting of 3 arms enrolling simultaneously: Roll-in, Paroxysmal AF, Persistent AF</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Demonstrate an acceptable safety profile of PVI ablation with the PulseSelect PFA System. The following PFA System-related and PFA procedure-related serious adverse events (SAEs) will be considered a primary safety event:</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Within 6 months post-ablation:&#xD;
Pulmonary vein stenosis (≥70% diameter reduction)&#xD;
Phrenic nerve injury/diaphragmatic paralysis (ongoing at 6 months)&#xD;
Atrioesophageal fistula&#xD;
Within 30 days of ablation procedure:&#xD;
Cardiac tamponade/perforation&#xD;
Cerebrovascular accident&#xD;
Major bleeding requiring transfusion&#xD;
Myocardial infarction&#xD;
Pericarditis requiring intervention&#xD;
Transient ischemic attack&#xD;
Vagal nerve injury resulting in esophageal dysmotility or gastroparesis&#xD;
Vascular access complications requiring intervention&#xD;
Systemic/pulmonary embolism requiring intervention&#xD;
Pulmonary edema&#xD;
Death&#xD;
Any PulseSelect PFA System-related or PFA procedure-related cardiovascular and/or pulmonary adverse event that prolongs or requires hospitalization for more than 48 hours (excluding recurrent AF/AFL/AT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness: Demonstrate an acceptable chronic effectiveness of PVI ablation with the PulseSelect PFA System, based on freedom from treatment failure.</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Treatment success is defined as freedom from treatment failure. The study requires 24-hour Holter monitoring at 6 and 12 months in addition to weekly and symptomatic patient activated ambulatory monitoring transmissions through 12 months, and 12-lead ECGs at all follow up visits. Treatment failure is defined as any of the following components:&#xD;
Acute procedural failure&#xD;
Documented AF/AT/AFL on Holter/patient activated ambulatory monitoring/12-lead ECG after the 90-day post-ablation blanking period.&#xD;
Any subsequent AF surgery or ablation in the left atrium, except for one repeat PVI ablation using PFA within the 90-day blanking period.&#xD;
Direct current cardioversion for atrial tachyarrhythmia recurrences after the 90-day blanking period.&#xD;
Class I or III antiarrhythmic drug (AAD) dose increase from the historic maximum ineffective dose (prior to the ablation procedure) or initiation of a new Class I or III AAD after the 90-day blanking period.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pilot Phase Safety: Assess the incidence of PFA System-related and PFA procedure-related serious adverse events (SAEs) within 30 days post-ablation.</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pilot Phase Effectiveness: Assess the acute procedural success of PVI ablation with the PFA System.</measure>
    <time_frame>Acute (day of procedure)</time_frame>
    <description>Acute procedural failure is defined as the occurrence of any of the following:&#xD;
Inability to isolate all accessible targeted pulmonary veins (assessed for entrance block and, where assessable, exit block) during the index ablation procedure.&#xD;
Ablation using a non-study device in the left atrium.&#xD;
Acute procedural success is the opposite of acute procedural failure.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal - Roll-In</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal - Paroxysmal AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pivotal - Persistent AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic PulseSelect Pulsed Field Ablation (PFA) System</intervention_name>
    <description>Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.</description>
    <arm_group_label>Pilot</arm_group_label>
    <arm_group_label>Pivotal - Paroxysmal AF</arm_group_label>
    <arm_group_label>Pivotal - Persistent AF</arm_group_label>
    <arm_group_label>Pivotal - Roll-In</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Failure of at least one AAD (class I or III) for AF as evidenced by recurrent&#xD;
             symptomatic AF, or intolerable side effects due to AAD.&#xD;
&#xD;
          2. A diagnosis of recurrent symptomatic paroxysmal or persistent AF:&#xD;
&#xD;
               1. Symptomatic paroxysmal AF, which is defined as AF that terminates spontaneously&#xD;
                  or with intervention within 7 days of onset, documented by the following:&#xD;
&#xD;
                    1. physician's note indicating at least 2 symptomatic paroxysmal AF episodes&#xD;
                       occurring within 6 months prior to enrollment; and&#xD;
&#xD;
                    2. at least 1 ECG documented AF episode from any form of rhythm monitoring&#xD;
                       within 12 months prior to enrollment OR&#xD;
&#xD;
               2. Symptomatic persistent AF, which is defined as continuous AF sustained beyond 7&#xD;
                  days and less than 1 year, documented by the following:&#xD;
&#xD;
                    1. physician's note indicating at least 1 symptomatic persistent AF episode&#xD;
                       occurring within 6 months prior to enrollment; and&#xD;
&#xD;
                    2. any 24-hour continuous ECG recording documenting continuous AF within 6&#xD;
                       months prior to enrollment; OR 2 ECGs from any form of rhythm monitoring&#xD;
                       taken at least 7 days apart, both showing continuous AF within 6 months&#xD;
                       prior to enrollment&#xD;
&#xD;
          3. Age 18 through 80 years old (or older than 18 if required by local law)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Long-standing persistent AF (continuous AF that is sustained &gt;12 months)&#xD;
&#xD;
          2. Left atrial diameter &gt; 5.0 cm (anteroposterior)&#xD;
&#xD;
          3. Prior left atrial ablation or surgical procedure (including left atrial appendage&#xD;
             closures)&#xD;
&#xD;
          4. Planned LAA closure procedure or implant of a permanent pacemaker, biventricular&#xD;
             pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable&#xD;
             cardiac defibrillator (with or without biventricular pacing function) for any time&#xD;
             during the follow-up period&#xD;
&#xD;
          5. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the&#xD;
             ablation procedure&#xD;
&#xD;
          6. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable&#xD;
             cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or&#xD;
             without biventricular pacing function)&#xD;
&#xD;
          7. Presence of any pulmonary vein stents&#xD;
&#xD;
          8. Presence of any pre-existing pulmonary vein stenosis&#xD;
&#xD;
          9. Pre-existing hemidiaphragmatic paralysis&#xD;
&#xD;
         10. Presence of any cardiac valve prosthesis&#xD;
&#xD;
         11. Moderate to severe mitral valve stenosis&#xD;
&#xD;
         12. More than moderate mitral regurgitation (i.e., 3+ or 4+ MR)&#xD;
&#xD;
         13. Any cardiac surgery, myocardial infarction, PCI / PTCA or coronary artery stenting&#xD;
             which occurred during the 3-month interval preceding the consent date&#xD;
&#xD;
         14. Unstable angina&#xD;
&#xD;
         15. NYHA Class III or IV congestive heart failure or documented left ventricular ejection&#xD;
             fraction (LVEF) less than or equal to 35% measure by acceptable cardiac testing (e.g.&#xD;
             TTE)&#xD;
&#xD;
         16. Primary pulmonary hypertension&#xD;
&#xD;
         17. Rheumatic heart disease&#xD;
&#xD;
         18. Thrombocytosis, thrombocytopenia&#xD;
&#xD;
         19. Any condition contraindicating chronic anticoagulation&#xD;
&#xD;
         20. Active systemic infection&#xD;
&#xD;
         21. Hypertrophic cardiomyopathy&#xD;
&#xD;
         22. Known reversible causes of AF, including but not limited to uncontrolled&#xD;
             hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity&#xD;
&#xD;
         23. Any cerebral ischemic event (strokes or TIAs) which occurred during the 6-month&#xD;
             interval preceding the consent date&#xD;
&#xD;
         24. History of thromboembolic event within the past 6 months or evidence of intracardiac&#xD;
             thrombus at the time of the procedure&#xD;
&#xD;
         25. Any woman known to be pregnant or breastfeeding, or any woman of childbearing&#xD;
             potential who is not on a reliable form of birth regulation method or abstinence&#xD;
&#xD;
         26. Patient with life expectancy that makes it unlikely 12 months of follow-up will be&#xD;
             completed&#xD;
&#xD;
         27. Current or anticipated participation in any other clinical trial of a drug, device or&#xD;
             biologic during the duration of the study not pre-approved by Medtronic&#xD;
&#xD;
         28. Known allergies or hypersensitivities to adhesives&#xD;
&#xD;
         29. Unwilling or unable to comply fully with study procedures and follow-up&#xD;
&#xD;
         30. Unable to provide own informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josh Treadway</last_name>
    <phone>763-526-1832</phone>
    <email>josh.b.treadway@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jen Diouf</last_name>
    <phone>763-526-2587</phone>
    <email>jen.r.diouf@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>205-971-7583</phone>
    </contact>
    <investigator>
      <last_name>Jose Osorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>970-624-1581</phone>
    </contact>
    <investigator>
      <last_name>Ethan Ellis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>301-877-5583</phone>
    </contact>
    <investigator>
      <last_name>Sarfraz Durrani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BayCare Saint Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>813-875-9000</phone>
      <phone_ext>280209</phone_ext>
    </contact>
    <investigator>
      <last_name>James Irwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>678-843-6093</phone>
    </contact>
    <investigator>
      <last_name>David DeLurgio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>312-926-7554</phone>
    </contact>
    <investigator>
      <last_name>Bradley Knight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>515-633-3845</phone>
    </contact>
    <investigator>
      <last_name>Robert Hoyt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>410-502-0517</phone>
    </contact>
    <investigator>
      <last_name>Hugh Calkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southcoast Health System</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>508-973-7775</phone>
    </contact>
    <investigator>
      <last_name>Nitesh Sood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>616-391-1162</phone>
    </contact>
    <investigator>
      <last_name>Andre Gauri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>248-898-3123</phone>
    </contact>
    <investigator>
      <last_name>David Haines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Rochester MN)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>507-255-7456</phone>
    </contact>
    <investigator>
      <last_name>Douglas Packer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>816-932-6275</phone>
    </contact>
    <investigator>
      <last_name>Sanjaya Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>201-447-8453</phone>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>860-994-8176</phone>
    </contact>
    <investigator>
      <last_name>Luigi Di Biase, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health - North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>516-562-4168</phone>
    </contact>
    <investigator>
      <last_name>Raman Mitra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health - Heart Rhythm Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>212-263-7704</phone>
    </contact>
    <investigator>
      <last_name>Larry Chinitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>828-274-6000</phone>
      <phone_ext>48112</phone_ext>
    </contact>
    <investigator>
      <last_name>John Rhyner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>216-442-3333</phone>
    </contact>
    <investigator>
      <last_name>Khaldoun Tarakji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>614-688-8252</phone>
    </contact>
    <investigator>
      <last_name>John Hummel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Saint Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>503-216-2170</phone>
    </contact>
    <investigator>
      <last_name>Alefiyah Rajabali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doylestown Hospital</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>215-933-0053</phone>
    </contact>
    <investigator>
      <last_name>Robert Sangrigoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>215-349-8446</phone>
    </contact>
    <investigator>
      <last_name>Frank Marchlinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center- UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>412-647-4463</phone>
    </contact>
    <investigator>
      <last_name>Sandeep Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>512-807-3150</phone>
    </contact>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>434-243-0046</phone>
    </contact>
    <investigator>
      <last_name>J. Michael Mangrum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>206-320-3917</phone>
    </contact>
    <investigator>
      <last_name>Darryl Wells, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+61 249214720</phone>
    </contact>
    <investigator>
      <last_name>Bradley Wilsmore, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Prash Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH / Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+43 73276764419</phone>
    </contact>
    <investigator>
      <last_name>Helmut Friedrich Pürerfellner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende av</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+32 50453727</phone>
    </contact>
    <investigator>
      <last_name>Mattias Duytschaever, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>(604) 875-5324</phone>
    </contact>
    <investigator>
      <last_name>Jason Andrade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>(519) 685-8500</phone>
      <phone_ext>x35994</phone_ext>
    </contact>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3G1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>(514) 934-1934</phone>
    </contact>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>(418) 656-8711</phone>
    </contact>
    <investigator>
      <last_name>Jean-Francois Sarrazin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMC - Clinique Ambroise Paré</name>
      <address>
        <city>Neuilly-sur-Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+33 146415079</phone>
    </contact>
    <investigator>
      <last_name>Alexandre Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+81 172395057</phone>
    </contact>
    <investigator>
      <last_name>Hirofumi Tomita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+81 776613111</phone>
    </contact>
    <investigator>
      <last_name>Hiroshi Tada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University, Medical Hospital</name>
      <address>
        <city>Bunkyō-Ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+81 358035670</phone>
    </contact>
    <investigator>
      <last_name>Tetsuo Sasano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jikei University</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+81 334331111</phone>
    </contact>
    <investigator>
      <last_name>Teiichi Yamane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>+31 883200900</phone>
    </contact>
    <investigator>
      <last_name>Lucas Boersma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Investigator</last_name>
      <phone>+34 915868794</phone>
    </contact>
    <investigator>
      <last_name>Angel Arenal Maiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

